Stage Two

The second stage of development for ABI’s ACLR device will add therapeutics, i.e., stem cells, autologous or exogenous growth factors or gene therapy.

A dynamic scaffold that delivers a therapeutic agent is a new paradigm in ACL reconstruction. Current static scaffolds (typically polymer-based) are not indicated in ACL repair, require time and conditions to facilitate tissue generation and deliver therapeutics only. Dynamic scaffolds enable immediate function while simultaneously delivering the bioactive agent, supporting tissue regeneration, reducing rehabilitation requirements and speeding return to normal activities.

The combination of a functional tissue scaffold with a therapeutic represents a fundamental advance in regenerative technologies. Unlike static delivery scaffolds, ABI’s project will “humanize” porcine tissue into implants which can function and are a dynamic scaffold for the delivery of therapeutics.

©2009 Aperion Biologics Corporation. All rights reserved. Privacy policy. Access to and use of this Web site is subject to these Terms of Use.